💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Jupiter Life Line Hospitals Limited is an India-based holding company. The Company is a multi-specialty tertiary and quaternary healthcare service provider in the Mumbai metropolitan area and western India. The Company has a total bed capacity of approximately 1,061 hospital…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, fairly priced.
JUPITER LIFE LINE HOSP L is scored on the pharma / healthcare framework. It keeps a healthy 12.6% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.38× reported profit. Free cash flow is worth about -1.9% of its market value.
Over the last 3 years revenue compounded at 20%/yr and profit at 39%/yr. Book value itself has compounded 62%/yr — the hallmark of a genuine compounder. Return on equity is a modest 11.4%. In the latest quarter profit grew 50% versus the prior quarter.
At 2× earnings, the stock sits at the 46th percentile of its own 3.2-year range — the middle of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 50.49 | 36.05 | worse |
| P/B | 5.78 | 3.87 | worse |
| EV/EBITDA | 25.47 | 14.33 | worse |
| ROE | 11.43 | 16.58 | worse |
| ROCE | 12.76 | 18.5 | worse |
| ROA | 7.29 | 10.62 | worse |
| Quick Ratio | 2.85 | 2.72 | better |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 20% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak. Profit is growing faster than revenue (39% vs 20%) — margin expansion is at work.
Operating margin has expanded from 14% to 17% — the business is keeping more of each rupee earned.
ROE at 13% — a respectable return on shareholder capital. Capital efficiency declining — ROE down 7pp.
Profit grew faster than EPS (39% vs 32%) — share dilution is eroding per-share value. 32% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.4× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 11% sequentially — momentum is building. Run-rate stepping up — recent quarters average 15% above earlier ones.
Profit jumped 50% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.2y median.
Promoters at 40.9% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.